The wellness market will continue to expand, and the infrastructure layer, not the molecules, is where durable returns are generated

Hims and Hers is the clearest public-market expression of the infrastructure thesis. It is not a pharmacy but a personalization and distribution platform; its moat is the direct consumer relationship, the data layer that matches patients to treatments, and the telehealth rails that deliver them. The financials confirm scale, with full-year 2025 revenue of roughly $2.35 billion, up 59% year over year, $318 million in adjusted EBITDA, and more than 2.5 million subscribers. The strategic logic is that the specific molecules dispensed, whether GLP-1s, generics, or future peptides, are interchangeable, while the platform that routes them to consumers is not. The company has expanded into at-home lab testing and personalized treatment plans, deepening the data advantage. The principal risk is regulatory and is live; the FDA's decision to end the semaglutide shortage exception in early 2025 threatened a major compounded-GLP-1 revenue stream, and the business operates in an environment that can shift quarter to quarter. For the thesis, Hims and Hers demonstrates that owning the distribution and personalization layer, rather than any single therapy, produces a scalable and defensible business as peptide medicine moves into mass consumer adoption.

Kailera Therapeutics is the venture-stage embodiment of the bet that the GLP-1 market is a floor rather than a ceiling. Founded in 2024, the company in-licensed a portfolio of metabolic assets from Hengrui and has raised more than $1 billion, including a $600 million Series B led by Bain Capital Private Equity in October 2025, a rare sum for a clinical-stage company. Its lead asset, KAI-9531, an injectable GLP-1/GIP dual agonist also known as ribupatide, entered a global Phase 3 program with potentially best-in-category weight loss, and the pipeline includes an oral GLP-1 and an injectable tri-agonist. The contrast with Novo Nordisk is the instructive part of the thesis. Novo built its franchise through decades of vertically integrated, internal peptide discovery that produced semaglutide, whereas Kailera is a capital-and-licensing model that acquires de-risked assets and races them through late-stage trials against the incumbents. The Metsera bidding war, in which Pfizer paid up to roughly $10 billion for a clinical-stage peptide developer, demonstrates the scale of incumbent appetite for exactly the next-generation obesity assets Kailera is advancing. The risk is that next-generation obesity drugs must demonstrate meaningful superiority over tirzepatide, an already highly effective benchmark.

Entera Bio addresses the single largest technical barrier to peptide adoption, which is that peptides are destroyed in the digestive tract and therefore typically require injection. Entera develops oral formulation technology designed to deliver peptides that are currently injectable-only, and in 2025 it partnered with OPKO Health to develop an oral GLP-1 and glucagon tablet for obesity. The strategic significance is leverage; oral delivery does not compete with the molecule developers, it enables all of them, which positions a successful platform to be licensed across the industry rather than tied to a single asset. Every major obesity player is racing toward oral formulations precisely because removing the injection barrier expands the addressable population by orders of magnitude. That is the infrastructure logic of the thesis applied to a hard chemistry problem. The risk is equally clear; oral bioavailability of peptides remains scientifically difficult, clinical success is far from guaranteed, and the OPKO partnership, while validating, is early. For the thesis, Entera represents the highest-leverage technical bet in the category, distinct from the distribution and clinical-service plays, because the company that solves oral peptide delivery captures value from the entire peptide market rather than any single therapy.

Fountain Life represents the model that converts wellness behavior into physician-supervised, evidence-based medicine. It operates a network of high-end longevity clinics offering whole-body MRI, AI-driven diagnostics, and personalized longevity protocols, sitting at the premium, diagnostic-first end of the wellness infrastructure thesis. The strategic argument is that as longevity and preventive medicine accumulate clinical evidence and, eventually, reimbursement pathways, the credentialing layer that pairs diagnostics with supervised intervention becomes the bridge from unregulated biohacking to legitimate healthcare. GLP-1 adoption strengthens this model directly, since the normalization of medical weight management has pulled millions of consumers into clinical wellness settings, creating a cross-selling opportunity for adjacent longevity services. The clear limitation is scalability; the current model is high cost and serves affluent consumers, and reimbursement remains the binding constraint on reaching a mainstream population. For the thesis, Fountain Life is the smallest-scale and most speculative of the four deep dives, included because it represents the clinical-credentialing function that, if longevity medicine achieves reimbursement, becomes a structurally valuable layer. It is the clearest illustration of wellness migrating into the formal healthcare stack rather than remaining in the supplement aisle.